title: Mechanism of emergency contraception with gestrinone: a preliminary investigation.
abstract: BACKGROUND
  A previous investigation showed that among 120 healthy women treated with a single oral dose of gestrinone for emergency contraception (EC), there was only one pregnancy. The effect of a single oral dose of gestrinone given for EC on ovarian function and endometrial development was studied.
  
  
  METHODS
  Healthy fertile women were randomly assigned to Group A (n=8) or Group B (n=7). Gestrinone 5 mg was orally administered to each woman before (Group A) or after (Group B) ovulation. The day of ovulation was determined by transvaginal ultrasound and by urinary luteinizing hormone (LH) measured by enzyme immunoassay (One Step LH Ovulation Test). An endometrial biopsy was performed during implantation. Endometrial maturation and expression of markers of endometrial receptivity were analyzed. The tested markers were integrins alpha(1)beta(1), alpha(4)beta(1) and beta(3). Serum estradiol (E(2)) and progesterone (P) levels in serum were determined by radioimmunoassay, and estradiol receptors and progesterone receptors (PRs) in the endometrium were assessed by immunohistochemistry.
  
  
  RESULTS
  Gestrinone administered during the periovulatory period did not affect follicular development, ovulation, menstrual cycle length and E(2) and P levels but decreased the expression of PR in the endometrium. Integrin alpha(4)beta(1) tended to increase after treatment with gestrinone without reaching statistical significance.
  
  
  CONCLUSIONS
  The mode of action of gestrinone used for EC is probably inhibition of implantation by acting on the endometrium rather than inhibition of ovulation.
authors: Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100083, China.
authors: Xuefeng
authors: X
authors: Gao
authors: Erruo
authors: E
authors: Wu
authors: Guian
authors: G
authors: Chen
mesh_terms: D000328:Adult; D044363:Contraception, Postcoital / Q000379:methods*; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D005260:Female; D005867:Gestrinone / Q000494:pharmacology*; D006801:Humans; D016023:Integrins / Q000378:metabolism; D008597:Menstrual Cycle / Q000187:drug effects; D006080:Ovarian Follicle / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D010865:Pilot Projects; D011374:Progesterone / Q000097:blood; D011372:Progestins / Q000494:pharmacology*; D011959:Receptors, Estradiol / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
chemical_list: D016023:Integrins; D011372:Progestins; D011959:Receptors, Estradiol; D011980:Receptors, Progesterone; D005867:Gestrinone; D011374:Progesterone; D004958:Estradiol